Parbendazole - CAS 14255-87-9
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
methyl N-(6-butyl-1H-benzimidazol-2-yl)carbamate; N-(6-Butyl-1H-benzimidazol-2-yl)carbamic Acid Methyl Ester; 5-Butyl-2-(carbomethoxyamino)benzimidazole; Helatac; Helmatac; Methyl (5-butyl-1H-benzimidazol-2-yl)carbamate; Methyl 5(6)-butyl-2-benzimidazolecarbamate; Methyl 5-butylbenzimidazole-2-carbamate; PBZ; PBZ (fungicide); Parbendazole; SKF 29044
CAS Number:
Parbendazole, a benzimidazole carbamat used as an antinematodal agent, is a potent inhibitor of microtubule assembly and functions.
Molecular Weight:
Molecular Formula:
Certificate of Analysis-Parbendazole 14255-87-9 B15W0630  
Canonical SMILES:
Catalog Number Size Price Stock Quantity
B0084-485433 500 mg $499 In stock
Bulk Inquiry
Chemical Structure
CAS 14255-87-9 Parbendazole

Related Microtubule/Tubulin Products

CAS 152044-54-7 Epothilone B

Epothilone B
(CAS: 152044-54-7)

Epothilone B, also called Patupilone, is a microtubule stabilization agent (EC0.01= 1.8 μM). It induces mitotic arrest at the G2-M transition in Hs578T (IC50 = ...

CAS 61-73-4 Methylene Blue

Methylene Blue
(CAS: 61-73-4)

Methylene Blue, whose brand name is Calbiochem, inhibits tau filament formation (IC50 = 1.9 μM) and soluble guanylyl cyclase.

CAS 90332-66-4 7-xylosyltaxol

(CAS: 90332-66-4)

7-xylosyltaxol is a taxol (Paclitaxel) derivative, which binds to tubulin and inhibits the disassembly of microtubules.

CAS 148408-66-6 Docetaxel Trihydrate

Docetaxel Trihydrate
(CAS: 148408-66-6)

Docetaxel is a cytotoxic agent, which is related to its ability to promote the formation of microtubule bundles and induce sustained mitotic arrest, followed by...


ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...


AADvac-1 is an active vaccine designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These ...

CAS 917111-49-0 Lexibulin dihydrochloride

Lexibulin dihydrochloride
(CAS: 917111-49-0)

Lexibulin dihydrochloride is an orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. It inh...

(CAS: 354759-10-7)

PBOX-15 is a novel microtubule inhibitor, which induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cel...

CAS 729605-21-4 XRP44X

(CAS: 729605-21-4)

XRP44X, under the IUPAC name [4-(3-chlorophenyl)piperazin-1-yl]-(5-methyl-2-phenylpyrazol-3-yl)methanone, as an inhibitor of Tubulin it indirectly inhibits Net ...

CAS 14255-87-9 Parbendazole

(CAS: 14255-87-9)

Parbendazole, a benzimidazole carbamat used as an antinematodal agent, is a potent inhibitor of microtubule assembly and functions.

CAS 194468-36-5 Vinflunine ditartrate

Vinflunine ditartrate
(CAS: 194468-36-5)

Vinflunine, a semisynthetic derivative of Vinorelbine, is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family endowed with uniqu...

CAS 6559-91-7 4'-Demethylepipodophyllotoxin

(CAS: 6559-91-7)

4'-Demethylepipodophyllotoxin is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs. It is a potent inhibitor of microtub...

CAS 33069-62-4 Taxol

(CAS: 33069-62-4)

Taxol, also called Paclitaxel, derived from the bark of the Pacific yew tree, has a broad antineoplastic spectrum uused in cancer chemotherapy.It promotes and s...

CAS 82855-09-2 Combretastatin

(CAS: 82855-09-2)

Combretastatin is a dihydrostilbenoid that found in Combretum caffrum. Members of the combretastatin family shows varying ability to cause vascular disruption i...

CAS 849550-05-6 Cevipabulin

(CAS: 849550-05-6)

Cevipabulin, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. With a novel mechanism of action distinct from th...

CAS 613-11-6 TRx 0237

TRx 0237
(CAS: 613-11-6)

TRx 0237, also called LMT-X or Methylene Blue, is a second-generation tau protein aggregation inhibitor currently in development for the treatment of Alzheimer'...

CAS 108852-90-0 Nemorubicin

(CAS: 108852-90-0)

Nemorubicin, currently being developed by Nerviano, is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumo...

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 117048-59-6 Combretastatin A4

Combretastatin A4
(CAS: 117048-59-6)

Combretastatin A4, under the IUPAC name 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol, inhibits tubulin polymerization (IC50= 2.2 μM). It has demons...

CAS 125317-39-7 Vinorelbine ditartrate

Vinorelbine ditartrate
(CAS: 125317-39-7)

Vinorelbine ditartrate, whose base is Vinorelbine, is a selective mitotic microtubule antagonist. It inhibits proliferation of Hela cells (IC50= 1.25 nM) and s...

Reference Reading

1.Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.
Arulanandam R1, Batenchuk C1, Varette O1, Zakaria C2, Garcia V1, Forbes NE1, Davis C1, Krishnan R1, Karmacharya R1, Cox J1, Sinha A1, Babawy A1, Waite K1, Weinstein E1, Falls T1, Chen A1, Hamill J1, De Silva N1, Conrad DP1, Atkins H1, Garson K1, Ilkow C1, Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410.
In this study, we show that several microtubule-destabilizing agents used for decades for treatment of cancer and other diseases also sensitize cancer cells to oncolytic rhabdoviruses and improve therapeutic outcomes in resistant murine cancer models. Drug-induced microtubule destabilization leads to superior viral spread in cancer cells by disrupting type I IFN mRNA translation, leading to decreased IFN protein expression and secretion. Furthermore, microtubule-destabilizing agents specifically promote cancer cell death following stimulation by a subset of infection-induced cytokines, thereby increasing viral bystander effects. This study reveals a previously unappreciated role for microtubule structures in the regulation of the innate cellular antiviral response and demonstrates that unexpected combinations of approved chemotherapeutics and biological agents can lead to improved therapeutic outcomes.
2.Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. I: Hexamita salmonis.
Tojo JL1, Santamarina MT. Dis Aquat Organ. 1998 May 14;33(1):51-6.
Various drugs were evaluated as regards efficacy for the treatment of Hexamita salmonis infection in rainbow trout. The results confirm the efficacy of nitroimidazoles: infection was completely eradicated not only by metronidazole (which has been recommended previously for the treatment of hexamitosis), but also by benznidazole, ronidazole and secnidazole, which have not been assayed previously. The non-nitroimidazoles albendazole, aminosidine, diethylcarbamazine and nitroscanate also completely eliminated infection. The remaining non-nitroimidazoles tested (amprolium, bithionol, febantel, flubendazole, levamisole, netobimin, niclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquentel, tetramisole, thiophanate, toltrazuril, trichlorfon and triclabendazole) were not effective.
3.Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin.
Upcroft J1, Mitchell R, Chen N, Upcroft P. Microb Drug Resist. 1996 Fall;2(3):303-8.
Albendazole resistance was induced in three different Giardia cultures following growth in successively increasing amounts of drug. One of the lines was previously resistant to high levels of metronidazole and was able to grow in 2 microM albendazole. The other two survived exposure to 0.8 microM, while normally lethal levels of albendazole against Giardia in vitro were around 0.1-0.2 microM. Albendazole-resistant Giardia were cross-resistant to parbendazole. Major chromosome rearrangements were evident in the line resistant to 2 microM albendazole and IFA with antitubulin antibody indicated differences in the cytoskeleton, particularly the median body, between sensitive and resistant lines. This implicates the cytoskeleton in the mechanism of resistance. Substitution of Tyr for Phe is a consistent beta-tubulin amino acid change in the benzimidazole-resistant helminths and fungi so far analyzed. PCR primers were designed from the published Giardia beta-tubulin gene sequence and spanned the region encoding Phe at position 200.
4.A new in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum.
Petersen MB1, Friis C, Bjørn H. Int J Parasitol. 1997 Nov;27(11):1333-9.
A new in vitro assay of benzimidazole activity against adult Oesophagostomum dentatum is described. The method is based on the ability of O. dentatum to migrate through polyamide nets after exposure to various concentrations of benzimidazole. To determine an appropriate mesh size, control worms and worms exposed to 10 microM oxfendazole for 24 h were allowed to migrate through nets with various mesh sizes (300-500 microns) for up to 1 h. A mesh size of 350 microns and migration periods of 10, 20 and 30 min were selected. Exposure to oxfendazole at 10 microM for 24, 48 and 72 h inhibited the migration in a time-dependent manner. After 72 h of exposure and with a 20-min migration period, the EC50 of oxfendazole for O. dentatum was 0.564 microM. In further studies the activities of albendazole sulphoxide, albendazole, cambendazole, fenbendazole, flubendazole, luxabendazole, mebendazole, oxfendazole, oxibendazole, parbendazole and thiabendazole were compared.